对被诊断为中部早发性青春期的患者进行了回顾性评估,这些患者已经达到最终的身高
Kadri Yaman1, Edip Unal1, Aslı Beştaş1
1Department of Pediatric Endocrinology, 2064056 Faculty of Medicine, Dicle University , Diyarbakır, Türkiye.
Journal of pediatric endocrinology & metabolism : JPEM
|June 17, 2024
概括
治疗中部早熟青春期 (CPP) 的淋巴激素释放激素类似物 (GnRHa) 有效地帮助大多数女孩达到或超过目标身高. 最初的身高和预测的成年人身高是实现更大的最终身高的关键因素.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 生殖医学 生殖医学
- 增长和发展 增长和发展
背景情况:
- 中部早期青春期 (CPP) 涉及青春期的早期发作,需要治疗以控制发育.
- CPP管理的主要目标是阻止或减缓青春期的进展.
- 评估影响GnRHa治疗患者最终身高的因素对于优化结果至关重要.
研究的目的:
- 为了确定与最终成年人身高相关的因素,GnRHa.治疗的女性CPP患者.
- 评估GnRHa治疗对体重指数 (BMI) 和青春期时间的影响.
- 为了确定录取参数和最终高度结果之间的关系.
主要方法:
- 对67名患有CPP的女性患者的医疗记录进行了回顾性分析.
- 收集的数据包括年龄,骨年龄 (BA),高度标准偏差得分 (SDS),BMI-SDS,目标高度-SDS和荷尔蒙水平.
- 还记录了盆腔超声检查结果和初潮时的年龄.
主要成果:
- 大多数患者 (94%) 在GnRHa治疗后达到或超过了目标身高.
- 超过目标身高的患者有更好的初始身高-SDS和预测的成人身高 (PAH).
- 目标身高-SDS对增高产生了积极的影响,而骨年龄与时间年龄 (BA/CA) 比例对其产生了负面影响. 治疗后BMI-SDS保持稳定.
结论:
- 在CPP的女孩中,GnRHa治疗有效地实现了令人满意的最终身高,其中很大一部分超过了他们的目标身高.
- 最初的高度-SDS和PAH是最终更高的重要预测因素.
- GnRHa疗法不会对BMI-SDS产生负面影响,支持其安全性.
相关概念视频
Signs of Puberty
318
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
318
Nature and Nurture
20.4K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.4K


